Chinese Academy of

Inactivated Poliomyelitis Vaccine (Sabin strains), designated IMBCAMS-03, is a vaccine candidate developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences for the prevention of poliomyelitis. The program is currently in Phase 3 clinical development as of the latest milestone dated 12 October 2023. The vaccine is classified as a monoclonal antibody modality, though the specific mechanism of action remains undisclosed. The sponsor has enrolled participants across multiple clinical trials registered in the United States (NCT01048190 and NCT01510366), indicating international trial activity. The program's Phase 3 completion status suggests advancement toward regulatory submission, though specific efficacy endpoints, safety data, and regulatory pathway decisions have not been disclosed. The vaccine addresses poliomyelitis prevention, a disease of significant global public health importance despite decades of eradication efforts. Competitive landscape includes established hexavalent vaccines such as INFANRIX HEXA (GlaxoSmithKline), which combines inactivated poliomyelitis vaccine with diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type-b components and holds European approval. The sponsor's development strategy appears focused on clinical validation through Phase 3 trials, with regulatory approval timelines and commercial plans not yet disclosed.

Poliomyelitis remains a public health priority despite successful global eradication campaigns, with endemic transmission persisting in select regions and ongoing vaccination requirements across immunization schedules worldwide. The development of inactivated poliomyelitis vaccines using Sabin strains represents a continued effort to optimize immunogenicity and safety profiles for routine childhood immunization programs. Market relevance is substantial given the universal inclusion of inactivated poliomyelitis vaccine in hexavalent and pentavalent combination immunizations across developed and developing nations. The global pediatric vaccine market encompasses billions of doses annually, with poliomyelitis components representing a significant segment. Competitive positioning against established products such as INFANRIX HEXA (approved in the European Union) and other combination vaccines requires demonstration of superior immunogenicity, safety, or manufacturing advantages. The patient population includes all infants and children requiring routine poliomyelitis immunization, representing hundreds of millions of potential recipients globally. Commercial significance depends on regulatory approval, pricing competitiveness, and adoption by national immunization programs and private healthcare systems. The sponsor's affiliation with a Chinese medical research institution suggests potential focus on Asian markets, where vaccine demand and manufacturing capacity represent major growth opportunities. Unmet medical needs may include improved thermostability, reduced injection volume, or enhanced immunogenicity in specific populations, though these have not been explicitly disclosed.

Drug Class: Inactivated viral vaccine

Modality: Monoclonal antibody (as classified in source data)

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Route of Administration: Not yet disclosed

Therapeutic Classification: Antiinfectives for systemic use (ATC J07)

Related Therapies: INFANRIX HEXA (GlaxoSmithKline Biologicals) — hexavalent vaccine combining diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis, and Haemophilus influenzae type-b; approved in European Union as of 12 February 2026 (EMEA/H/C/000296)

Patent Status: Not yet disclosed

First Approval: Not yet disclosed; program remains in Phase 3 clinical development

China (NMPA): Clinical trials ongoing; regulatory status not yet disclosed. Multiple inactivated poliomyelitis vaccine trials registered in China (NCT01244464, NCT03001986, NCT05148949, NCT05198336, NCT05365724).

United States (FDA): Phase 3 trials registered (NCT01048190, NCT01510366); FDA approval status not yet disclosed.

European Union (EMA): Regulatory status not yet disclosed. Reference product INFANRIX HEXA (GlaxoSmithKline Biologicals) approved under EMEA/H/C/000296 as of 12 February 2026.

Japan (PMDA): Regulatory status not yet disclosed.

Approval Timeline: Not yet disclosed. Expected next regulatory milestone not yet disclosed.

Development Status: The program has completed Phase 3 clinical development as of October 2023, indicating advancement toward regulatory submission. However, the absence of disclosed efficacy data, safety summaries, or regulatory pathway decisions limits assessment of approval probability and timeline.

Strategic Positioning: Xiyuan Hospital's affiliation with the China Academy of Chinese Medical Sciences suggests institutional focus on Chinese market development and potential partnerships with Chinese vaccine manufacturers or government immunization programs. The international trial registration (US-based NCTs) indicates broader regulatory ambitions beyond China.

Competitive Implications: IMBCAMS-03 enters a mature market dominated by established hexavalent vaccines (INFANRIX HEXA, HEXYON) with decades of safety and efficacy data. Differentiation would require demonstrated advantages in immunogenicity, safety profile, manufacturing cost, or thermostability. Absence of disclosed competitive advantages limits market penetration probability.

Regulatory Catalysts: Expected milestones include Phase 3 data publication, regulatory submissions to NMPA (China), FDA, and EMA, and potential approval decisions. Timeline for these catalysts remains undisclosed.

Market Access: Adoption depends on national immunization program inclusion, pricing competitiveness, and healthcare provider acceptance. Chinese market entry may precede Western regulatory approvals given sponsor location and trial activity.

Data Gaps: Critical information not yet disclosed includes immunogenicity endpoints, safety profile, manufacturing process, patent landscape, and regulatory strategy. Publication of Phase 3 results will be essential for competitive assessment.